This “hidden” research system, which operates outside of the patent system, has huge potential to regularly provide society with affordable treatments. Examples of this have included using a cancer drug to treat a leading cause of blindness, changing a drug from treating breast cancer to preventing it, and using an old anti-inflammatory drug to treat Covid. The new research led by King’s College London and published in the Cambridge Law Journal explores the parallel drug innovation system taking...